Incyte Corporation
$23.73B- Market cap
- $25.32B
- Debt
- +$1.51B
- Cash
- −$3.10B
Capital structure 94% equity / 6% debt · EV / Revenue 4.62x · EV / EBITDA 13.50x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 ·
Decision snapshot: INCY stock price at discount vs ROK $126.75 current versus $362.55 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ROK's multiple
Implied fair value · at INCY's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple discount
Value edge
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: INCY FY 2025 (ended Dec 31, 2025) · ROK FY 2025 (ended Sep 30, 2025). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 94% equity / 6% debt · EV / Revenue 4.62x · EV / EBITDA 13.50x
Capital structure 95% equity / 5% debt · EV / Revenue 6.03x · EV / EBITDA 33.13x
ROK carries the larger enterprise value at $50.32B against $23.73B; INCY trades on the lower EV / Revenue multiple (4.62x vs 6.03x); INCY on the lower EV / EBITDA (13.50x vs 33.13x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
INCYTE CORPORATION · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Rockwell Automation, Inc. · implied price per share
Bear
$103.76
Base
$128.85
Bull
$162.70
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.29x
0.72x
Net debt / EBITDA
Leverage against operating earnings
-0.90x
1.41x
Cash and equivalents
Liquid reserves on the balance sheet
$3.10B
$468.00M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMGEN INC
INCY vs AMGN
GILEAD SCIENCES, INC.
INCY vs GILD
VERTEX PHARMACEUTICALS INC / MA
INCY vs VRTX
REGENERON PHARMACEUTICALS, INC.
INCY vs REGN
BIOGEN INC.
INCY vs BIIB
EMERSON ELECTRIC CO
INCY vs EMR
Parker-Hannifin Corp
INCY vs PH
DANAHER CORP /DE/
INCY vs DHR
TERADYNE, INC
INCY vs TER
Eaton Corp plc
INCY vs ETN
COGNEX CORP
INCY vs CGNX
$1.51B
$2.62B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.